The in vitro antibacterial activities of YM-13115, a new parenteral cephalosporin, were compared with those of ceftazidime, cefoperazone, and cefsulodin. The compound was highly active against the common members of the Enterobacteriaceae and 2 to 256 times more active than cefoperazone. YM-13115 shown in Fig. 1. Matsui et al. (8) examined the pharmacokinetics of YM-13115 in animals and showed that this compound gives rise to high and persistent plasma levels in monkeys. In this paper we report a comparison of the in vitro activities of YM-13115 with those of ceftazidime (17), cefoperazone (6), and cefsulodin (16) against various grampositive cocci, members of the Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae. In addition, we report on the bactericidal activity of YM-13115 and its susceptibility to P-lactamases.MATERIALS AND METHODS Antibiotics. YM-13115 and ceftazidime were synthesized for this study in the Central Research Laboratories of Yamanouchi Pharmaceutical Co., Ltd. Cefoperazone and ampicillin (both from Toyama Chemical Co., Ltd., Toyama, Japan), cefsulodin (Takeda Chemical Industries, Osaka, Japan), cephaloridine (Shionogi Pharmaceutical Co., Ltd., Osaka, Japan), and potassium benzylpenicillin (Meiji Seika Kaisha, Ltd., Tokyo, Japan) were obtained commercially.